PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF

• Andrew Kuykendall,
• Terrence Bradley,
• Rami S. Komrokji,
• Tymara Berry,
• Souria Dougherty,
• Laurie Sherman,
• Lixian Peng,
• Fei Huang,
• Ying Wan,
• Vivian Rodolf,
• Judy Ho,
• Shyamala Navada,
• John Mascarenhas

Affiliations

Andrew Kuykendall

1 Moffitt Cancer Center, Tampa, United States

Terrence Bradley

2 Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, United States

Rami S. Komrokji

1 Moffitt Cancer Center, Tampa, United States

Tymara Berry

3 Geron Corporation, Parsippany, United States

Souria Dougherty

3 Geron Corporation, Parsippany, United States

Laurie Sherman

3 Geron Corporation, Parsippany, United States

Lixian Peng

3 Geron Corporation, Parsippany, United States

Fei Huang

3 Geron Corporation, Parsippany, United States

Ying Wan

3 Geron Corporation, Parsippany, United States

Vivian Rodolf

3 Geron Corporation, Parsippany, United States

Judy Ho

3 Geron Corporation, Parsippany, United States

Shyamala Navada

3 Geron Corporation, Parsippany, United States

John Mascarenhas

4 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States